AHA: Crestor, Lipitor both shine in high-dose SATURN trial

Links shared publicly online about this topic.

0
total visits

AHA: Crestor, Lipitor both shine in high-dose SATURN trial

Both rosuvastatin (Crestor, AstraZeneca) and atorvastin (Lipitor, Pfizer) at maximum dose lowered LDL cholesterol levels, raised HDL levels and reduced atherosclerotic plaque in the SATURN trial, the study’s lead researcher reported Nov. 15 at the 2011 American Heart Association (AHA) conference. While the Phase 2 clinical trial failed to find any significant difference between the two drugs’ ability to limit or reverse progression of coronary artery disease, it showed that a high-dose regime is

View full resource at cardiovascularbusiness.com

Tags: Heart, Cholesterol, Cholesterol Medication, American Heart Association, Lipitor, Crestor, Pfizer, AstraZeneca